0.96
+6.67%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Brainstorm Cell Therapeutics
From its filings with the US Securities and Exchange Commission
Brainstorm Cell Therapeutics is based in New York, New York and is incorporated in Delaware. Its shares trade on OTC under the ticker BCLI. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $10.3m. At that date it held total assets of $1.0m and shareholders' equity of −$10.0m.
Brainstorm Cell Therapeutics Inc. is a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”, also known as Lou Gehrig’s disease), progressive multiple sclerosis (“PMS”), Alzheimer’s disease (“AD”), and other neurodegenerative diseases. NurOwn®, our proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (“MSCs”) to secrete high levels of neurotrophic factors (“NTFs”), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.
NurOwn® has completed its Phase 3 ALS and Phase 2 PMS clinical trials. On November 17, 2020, we announced top-line data from our Phase 3 ALS trial. On March 24, 2021, we announced positive top-line data from our Phase 2 trial evaluating three repeated intrathecal administrations of NurOwn®, each given 2 months apart, as a treatment for PMS. On June 24, 2020, we announced a new clinical program focused on the development of NurOwn® as a treatment for AD.
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 May 2003
- Employees
- 20
- Website
- brainstorm-cell.com ↗
- Head office
- 1325 AVENUE OF AMERICAS, NEW YORK, NY, 10019
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Prof. Jacob FrenkelIndependent Chairman of the Board, since 2020$152,811
- Mr. Chaim LebovitsPresident, Chief Executive Officer$750,303
- Dr. Irit ArbelIndependent Vice Chairman of the Board, since 2004$148,012
- Ms. Alla PatlisInterim Chief Financial Officer, Controller$146,783
- Dr. Hartoun HartounianExecutive Vice President, Chief Operating Officer
- Mr. Uri YablonkaDirector, Executive Vice President, Chief Business Officer, Secretary, since 2014$266,138
- Dr. Ibrahim DagherExecutive Vice President, Chief Medical Officer$498,578
- Dr. Stacy LindborgDirector, since 2020$346,375
- Dr. Menghisteab BairuIndependent Director$60,000
- Mr. Nir NaorIndependent Director
- Dr. Anthony PolverinoIndependent Director$12,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 40
- Environment
- 40
- Social
- 51
- Governance
- 29
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Brainstorm Cell Therapeutics Inc. has a subsidiary, Brainstorm Cell Therapeutics Ltd., which holds rights to commercialize NurOwn in Israel.
- The company completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center.
- Brainstorm Cell Therapeutics Inc. is headquartered in New York City, New York, with 20 employees.
Weaknesses
- The company has only one product line, NurOwn, in clinical development for ALS treatment.
- Brainstorm Cell Therapeutics Inc. has a small workforce of 20 employees.
- The company's IPO occurred in 2003, indicating a long history without recent market activity.
Opportunities
- NurOwn is in clinical development for the treatment of ALS, a condition with significant unmet medical needs.
- The Israeli Subsidiary holds rights to commercialize NurOwn, expanding potential market reach.
- The company has completed clinical trials at Hadassah Medical Center, which could facilitate future regulatory approvals.
Threats
- The company's sole focus on NurOwn for ALS treatment leaves it vulnerable to clinical trial failures.
- Brainstorm Cell Therapeutics Inc. has only 20 employees, which may limit its capacity to manage multiple projects.
- The biotechnology sector is highly competitive, with many companies developing similar therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.